I
ImmunityBio
ImmunityBio pioneers innovative therapies to conquer disease through immune system reprogramming
About ImmunityBio
ImmunityBio is a biotechnology company focused on developing innovative immunotherapies to treat cancer and infectious diseases. The company operates in the healthcare and pharmaceutical markets, primarily serving patients with difficult-to-treat conditions such as advanced metastatic prostate cancer, pancreatic cancer, and non-small cell lung cancer. ImmunityBio's business model revolves around the research, development, and commercialization of therapies that enhance the immune system rather than weaken it. This approach includes natural killer cell-based therapies and viral vector vaccines, which have shown promising results in clinical trials. The company generates revenue through the sale of its immunotherapy products and potential licensing agreements with other pharmaceutical companies. ImmunityBio's investigational therapies have demonstrated wide therapeutic potential and are well-tolerated, making them ideal candidates for clinical trials. The company aims to outsmart diseases by leveraging the body's natural defenses, providing hope for patients with limited treatment options.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
Open roles
ImmunityBio in the Culver City ecosystem
The ImmunityBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
NantCell | Nantworks
Series B and later2 investors entered at this stage
- NCNant Capital
Oberland Capital
Source: Dealroom Talent Intelligence.
Global footprint
Patents
189 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See ImmunityBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer
ImmunityBio secures UAE marketing authorisation for ANKTIVA in bladder and lung cancers

